Skip to main content

Table 4 Median ± interquartile range for various laboratory variables before and after 12 weeks of treatment with cholecalciferol or PBO for patients with measurements of hepcidin-25 available at baseline and week 12 (n = 85)

From: The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease

Parameter

Cholecalciferol (n = 42)

 

PBO (n = 43)

 
 

Baseline

Week 12

p-value

Baseline

Week 12

p-value

 Hemoglobin (g/L)

126 (119, 137)

130 (115, 138)

0,45

135 (120, 145)

131 (118, 140)

0,09

 Hematocrit (%)

38 (36, 41)

37 (35, 41)

0,90

41 (37, 43)

40 (36, 42)

0,06

 Erythrocytes (1012/L)

4,1 (3,9, 4,6)

4,0 (3,8, 4,5)

0,25

4,3 (4,0, 4,8)

4,3 (3,9, 4,8)

0,08

 25(OH)D (nmol/L)

54 (39, 71)

156 (120, 190)

 < 0,01

59 (39, 72)

57 (42, 79)

0,12

 1,25(OH)2D (pmol/L)

56 (26, 92)

86 (60, 138)

 < 0,01

53 (34, 90)

59 (38, 82)

0,95

 hepcidin-25 (nmol/L)

5,3 (3,0, 10,5)

4,8 (3,0, 9,8)

0,28

4,5 (1,9, 7,5)

3,7 (2,2, 6,6)

0,66

 hepcidin / ferritin ratio

46 (23, 61)

45 (24, 63)

0,20

31 (16, 42)

33 (19, 51)

0,40

 ferritin (µg/L)

124 (77, 257)

140 (73, 246)

0,46

142 (73, 239)

115 (67, 255)

0,28

 CRP (mg/L)

2,0 (0,71, 4,4)

4,0 (1,3, 7,6)

0,03

2,2 (1,3, 5,4)

3,4 (1,2, 7,7)

0,06

 TSAT (%)

26 (19, 34)

26 (19, 32)

0,24

26 (19, 32)

23 (18, 31)

0,07

 S-iron (µmol/L)

17 (13, 21)

14 (11, 19)

0,14

17 (13, 19)

15 (11, 19)

0,047

 IL-6, (ng/L)

1,8 (1,0, 3,5)

2,1 (1,1, 4,2)

0,10

3,0 (1,2, 4,5)

2,8 (1,5, 4,7)

0,15

 eGFR (mL/min/1,73m2)

29 (22, 40)

30 (21, 42)

0,15

28 (20, 40)

28 (17, 38)

0,02

 Calcium (mmol/L)

2,25 (2,17, 2,32)

2,23 (2,16, 2,29)

0,93

2,27 (2,21, 2,35)

2,23 (2,17, 2,31)

 < 0,01

 Phosphate (mmol/L)

1,2 (1,0, 1,3)

1,3 (1,1, 1,4)

0,04

1,11 (1,0, 1,3)

1,3 (1,0, 1,4)

0,11

 FGF-23 (pg/mL)

92 (68, 164)

122 (70, 194)

 < 0,01

131 (70, 181)

108 (81, 216)

0,22

Patients with 25-(OH)D < 56 nmol/L

Cholecalciferol (n = 22)

 

PBO (n = 19)

p-value

 Hemoglobin (g/L)

122 (117, 135)

126 (113,138)

0,22

138 (117, 150)

131 (114, 144)

0,07

 Hematocrit (%)

36 (35, 41)

37 (35, 41)

0,07

41 (36, 44)

40 (35, 44)

0,02

 Erythrocytes (1012/L)

4,1 (3,6, 4,6)

4,1 (3,8, 4,6)

0,44

4,4 (4,1, 5,1)

4,3 (3,8, 4,9)

0,02

 25(OH)D (nmol/L)

39 (31–50)

124 (106, 158)

 < 0,01

37 (31, 43)

42 (38, 51)

0,02

 1,25(OH)2D (pmol/L)

39 (9–77)

81 (48, 122)

 < 0,01

49 (35, 76)

60 (44, 86)

0,65

 hepcidin-25 (nmol/L)

6,2 (2,8, 12)

6,1 (3,2, 14)

0,78

4,5 (1,9, 7,1)

3,0 (2,2, 5,5)

0,72

 hepcidin / ferritin ratio

47 (27, 55)

45 (29, 67)

0,88

32 (18, 54)

32 (22, 51)

0,98

 ferritin (µg/L)

138 (80, 341)

149 (83, 328)

0,75

133 (76, 238)

113 (79, 186)

0,27

 CRP (mg/L)

1,9 (0,8, 4,4)

4,4 (1,6, 7,7)

0,02

3,3 (2,0, 10,1)

5,5 (1,5, 21,5)

0,18

 TSAT (%)

24 (19, 34)

25 (19, 32)

0,67

25 (16, 32)

21 (14, 25)

0,01

 S-iron (µmol/L)

16 (12, 17)

15 (11, 20)

0,74

17 (12, 19)

15 (10, 15)

0,02

 IL-6 (ng/L)

2,8 (0,9, 4,3)

3,4 (1,6, 5,5)

0,06

3,3 (1,6, 4,5)

3,7 (1,9, 8,4)

0,07

 e GFR (mL/min/1,73m2)

29 (22–39)

31 (20–44)

0,17

34 (28, 47)

34 (21, 41)

0,03

 Calcium (mmol/L)

2,20 (2,03–2,27)

2,23 (2,13–2,30)

0,18

2,27 (2,20, 2,30)

2,24 (2,15, 2,28)

0,01

 Phosphate (mmol/L)

1,1 (1,0, 1,3)

1,3 (1,1, 1,5)

0,03

1,2 (1,0, 1,4)

1,3 (1,0, 1,5)

0,11

 FGF-23 (pg/mL)

91 (70, 78)

127 (70, 275)

0,02

112 (53, 164)

101 (64, 166)

0,5

Patients with 25-(OH)D ≥ 56 nmol/L

Cholecalciferol (n = 20)

 

PBO (n = 24)

 

 Hemoglobin (g/L)

129 (121, 141)

126 (116, 140)

0,01

131 (119, 140)

132 (119, 137)

0,59

 Hematocrit (%)

39 (36, 42)

37 (35, 42)

0,049

38 (37, 42)

39 (36, 42)

0,64

 Erythrocytes (1012/L)

4,3 (3,9, 4,6)

4,0 (3,8, 4,4)

0,02

4,2 (3,9, 4,7)

4,2 (3,9, 4,7)

0,97

 25(OH)D (nmol/L)

71 (61, 81)

184 (156, 220)

 < 0,01

72 (64, 87)

76 (59, 86)

0,49

 1,25(OH)2D (pmol/L)

67 (45, 103)

102 (72, 152)

 < 0,01

60 (33, 95)

54 (36, 81)

0,72

 hepcidin-25 (nmol/L)

5,1 (3,1, 7,2)

4,3 (2,4, 7,0)

0,04

4,3 (1,6, 8,4)

4,3 (2,1, 7,1)

0,37

 hepcidin / ferritin ratio

40 (21, 81)

44 (18, 54)

0,04

29 (15, 41)

35 (18, 52)

0,29

 ferritin (µg/L)

108 (76, 242)

109 (72, 209)

0,56

142 (41, 276)

137 (59, 272)

0,65

 CRP (mg/L)

2,4 (0,7, 7,1)

3,4 (0,9, 7,4)

0,55

1,7 (0,9, 4,4)

2,6 (0,8, 5,9)

0,16

 TSAT (%)

28 (20, 34)

22 (17, 26)

0,056

27 (19, 35)

26 (20, 38)

0,88

 S-iron (µmol/L)

17 (13, 22)

13 (12, 17)

0,1

17 (13, 20)

16 (13, 21)

0,67

 IL-6 (ng/L)

1,4 (1,0, 2,5)

1,7 (1,0, 2,5)

0,57

2,0 (0,95, 4,3)

2,3 (1,2, 4,3)

0,82

 e GFR (mL/min/1,73m2)

30 (24, 44)

30 (25, 42)

0,68

21 (18, 32)

24 (16, 35)

0,24

 Calcium (mmol/L)

2,27 (2,22, 2,37)

2,22 (2,19, 2,29)

0,052

2,27 (2,21, 2,39)

2,23 (2,17, 2,31)

0,01

 Phosphate (mmol/L)

1,2 (1,0, 1,3)

1,3 (1,1, 1,3)

0,68

1,1 (0,9, 1,3)

1,1 (1,0, 1,3)

0,46

 FGF-23 (pg/mL)

100 (59, 157)

106 (69, 175)

0,01

139 (78, 252)

145 (84, 258)

0,35

  1. Values are presented as median and interquartile range. p-values refer to changes over time from baseline to week 12 within each group. p-values in bold denotes a value < 0,05. Sub-group analyses are based on patients with baseline values of 25-hydroxyvitamin D below, and above (or equal to), the median value of 56 nmol /L, respectively. e GFR, estimated glomerular filtration rate; TSAT, transferrin saturation; CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2, 1,25-dihydroxyvitamin D; FGF-23: fibroblast growth factor 23
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us